Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Druyts

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Journal of Managed Care & Specialty Pharmacy|October 29, 2020
ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraineMeg Franklin, Eric Druyts
AIDS (London, England)|May 31, 2013
Engaging men in HIV treatment and careEric Druyts, Edward J Mills
Journal of Clinical Epidemiology|July 4, 2020
Is it always possible to complete a systematic review in 2 weeks? Further thoughts and considerationsKevin Yan, Chakrapani Balijepalli, Eric Druyts
Frontiers in Digital Health|October 29, 2021
The Impact of Digital Therapeutics on Current Health Technology Assessment FrameworksKevin Yan, Chakrapani Balijepalli, Eric Druyts
Journal of Medical Economics|April 8, 2014
Letter to the editorEric Druyts, Kristian Thorlund, Edward J Mills
Clinical Epidemiology|January 30, 2014
SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirinKristian Thorlund, Eric Druyts, Edward J Mills
Systematic Reviews|October 15, 2014
The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysisEric Druyts, Shawn Eapen, Ping Wu, et al.
Pharmacoeconomics|September 14, 2020
On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?Kamal Desai, Eric Druyts, Kevin Yan, et al.
Current Medical Research and Opinion|September 13, 2021
Changing face of healthcare: digital therapeutics in the management of diabetesPriyadharshini Ramakrishnan, Kevin Yan, Chakrapani Balijepalli, et al.
Journal of Medical Economics|January 29, 2015
Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitisKabirraaj Toor, Eric Druyts, Jeroen P Jansen, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Journal of Managed Care & Specialty Pharmacy|October 29, 2020
ICER's assessment of lasmiditan, rimegepant, and ubrogepant for acute migraineMeg Franklin, Eric Druyts
AIDS (London, England)|May 31, 2013
Engaging men in HIV treatment and careEric Druyts, Edward J Mills
Journal of Clinical Epidemiology|July 4, 2020
Is it always possible to complete a systematic review in 2 weeks? Further thoughts and considerationsKevin Yan, Chakrapani Balijepalli, Eric Druyts
Frontiers in Digital Health|October 29, 2021
The Impact of Digital Therapeutics on Current Health Technology Assessment FrameworksKevin Yan, Chakrapani Balijepalli, Eric Druyts
Journal of Medical Economics|April 8, 2014
Letter to the editorEric Druyts, Kristian Thorlund, Edward J Mills
Clinical Epidemiology|January 30, 2014
SVR12 is higher than SVR24 in treatment-naïve hepatitis C genotype 1 patients treated with peginterferon plus ribavirinKristian Thorlund, Eric Druyts, Edward J Mills
Systematic Reviews|October 15, 2014
The risk of elevated prolactin levels in pediatric patients exposed to antipsychotics for the treatment of schizophrenia and schizophrenia spectrum disorders: protocol for a systematic review and meta-analysisEric Druyts, Shawn Eapen, Ping Wu, et al.
Pharmacoeconomics|September 14, 2020
On Pandemic Preparedness: How Well is the Modeling Community Prepared for COVID-19?Kamal Desai, Eric Druyts, Kevin Yan, et al.
Current Medical Research and Opinion|September 13, 2021
Changing face of healthcare: digital therapeutics in the management of diabetesPriyadharshini Ramakrishnan, Kevin Yan, Chakrapani Balijepalli, et al.
Journal of Medical Economics|January 29, 2015
Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitisKabirraaj Toor, Eric Druyts, Jeroen P Jansen, et al.
Pageof 7